SCoV-2 Ag Detect™ Rapid Test

Home Page SCoV-2 Ag Detect™ Rapid Test

FDA Emergency Use Authorized

SCoV-2 Ag Detect™ Rapid Test

SCoV-2 Ag Detect™ Rapid Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 Nucleoprotein antigen in direct anterior nasal swab specimens from individuals who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Key Features/Performance

Downloads

Letter of AuthorizationDownload
Fact Sheet for Healthcare ProvidersDownload
Fact Sheet for PatientsDownload
InBios IFUDownload
InBios QRGDownload
Flyer Autumn DiagnosticsDownload